New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer
Activity Info
Suresh S. Ramalingam, MD and Heather A. Wakelee, MD
Hear about recent evidence related to identification of molecular patterns to predict response to EGFR inhibitors, learn to integrate newly approved and emerging EGFR inhibitors into the treatment plan for NSCLC, and see how to manage resistance to first-generation EGFR inhibitors.